A Phase 1 interventional study of 1 tablet Empagliflozin/2 tablets Metformin XR and 10 mg Empagliflozin/1000 mg Metformin XR in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin \& metformin XR and the single tablets of empagliflozin and metformin XR when administered singularly
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Any deviation from healthy condition
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
Drug: 10 mg Empagliflozin/1000 mg Metformin XR · Drug: 1 tablet Empagliflozin/2 tablets Metformin XR
1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
Drug: 1 tablet Empagliflozin/2 tablets Metformin XR · Drug: 10 mg Empagliflozin/1000 mg Metformin XR
2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR · Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR
Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
Drug pages: Empagliflozin · Metformin
Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
Drug pages: Empagliflozin · Metformin
Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin
Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Metformin
Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Empagliflozin
Maximum measured concentration of empagliflozin in plasma (Cmax).
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Metformin
Maximum measured concentration of metformin in plasma
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Empagliflozin
Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity).
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Metformin
Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 20min, 1h 40min, 2h, 2.5h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, 10h, 12h, 16h, 24h, 36h, 48h and 72h after drug administration
| Milestone | Empa+1000mg Met FDC / Empa+1000mg Glumetza® (Fasted) | Empa+1000mg Glumetza / Empa+1000mg Met FDC (Fasted) | Empa+1000mg Met FDC / Empa+1000mg Glumetza (Fed) | Empa+1000mg Glumetza / Empa+1000mg Met FDC (Fed) | Empa+1500mg Met FDC / Empa+1500mg Glumetza (Fasted) | Empa+1500mg Glumetza / Empa+1500mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 12 | 12 |
| Completed | 12 | 12 | 12 | 12 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).
| nmol*h/L | Empa/1000 mg Glumetza® (Fasted) | Empa/ 1000 mg Met FDC (Fasted) | Empa/1000 mg Glumetza ® (Fed) | Empa/ 1000 mg Met FDC (Fed) | Empa/ 1500 mg Glumetza® (Fasted) | Empa/ 1500 mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point), for Empagliflozin | 2630 ± 18.9 | 2710 ± 18.3 | 2720 ± 20.5 | 2710 ± 19.9 | 2790 ± 17.3 | 2680 ± 18.7 |
Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point
| ng*h/mL | Empa/1000 mg Glumetza® (Fasted) | Empa/ 1000 mg Met FDC (Fasted) | Empa/1000 mg Glumetza ® (Fed) | Empa/ 1000 mg Met FDC (Fed) | Empa/ 1500 mg Glumetza® (Fasted) | Empa/ 1500 mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| AUC0-tz (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) for Metformin | 7020 ± 35.2 | 7170 ± 36.2 | 13500 ± 19.1 | 13200 ± 18.8 | 9860 ± 26.4 | 10100 ± 25.6 |
Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity).
| nmol*h/L | Empa/1000 mg Glumetza® (Fasted) | Empa/ 1000 mg Met FDC (Fasted) | Empa/1000 mg Glumetza ® (Fed) | Empa/ 1000 mg Met FDC (Fed) | Empa/ 1500 mg Glumetza® (Fasted) | Empa/ 1500 mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Empagliflozin | 2680 ± 18.7 | 2760 ± 17.9 | 2790 ± 21.3 | 2770 ± 20.2 | 2840 ± 17.4 | 2740 ± 19.5 |
Maximum measured concentration of empagliflozin in plasma (Cmax).
| nmol/L | Empa/1000 mg Glumetza® (Fasted) | Empa/ 1000 mg Met FDC (Fasted) | Empa/1000 mg Glumetza ® (Fed) | Empa/ 1000 mg Met FDC (Fed) | Empa/ 1500 mg Glumetza® (Fasted) | Empa/ 1500 mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Empagliflozin | 377 ± 22.5 | 395 ± 24.6 | 273 ± 27.6 | 277 ± 31.0 | 396 ± 21.9 | 381 ± 22.0 |
Maximum measured concentration of metformin in plasma
| ng/mL | Empa/1000 mg Glumetza® (Fasted) | Empa/ 1000 mg Met FDC (Fasted) | Empa/1000 mg Glumetza ® (Fed) | Empa/ 1000 mg Met FDC (Fed) | Empa/ 1500 mg Glumetza® (Fasted) | Empa/ 1500 mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| Cmax (Maximum Measured Concentration of the Analyte in Plasma, for Metformin | 975 ± 37.2 | 964 ± 39.9 | 1110 ± 21.2 | 1200 ± 22.7 | 1220 ± 32.8 | 1270 ± 34.7 |
Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity
| ng*h/mL | Empa/1000 mg Glumetza® (Fasted) | Empa/ 1000 mg Met FDC (Fasted) | Empa/1000 mg Glumetza ® (Fed) | Empa/ 1000 mg Met FDC (Fed) | Empa/ 1500 mg Glumetza® (Fasted) | Empa/ 1500 mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| AUC0-infinity (Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity), for Metformin | 7480 ± 37.4 | 7360 ± 36.7 | 13900 ± 20.7 | 13600 ± 20.4 | 10500 ± 28.5 | 10900 ± 28.7 |
Collected over From drug administration until next treatment period or follow-up visit, 10 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empa/1000 mg Glumetza® (Fasted) | — | 0/24 (0%) | 4/24 (16.7%) |
| Empa/ 1000 mg Met FDC (Fasted) | — | 0/24 (0%) | 5/24 (20.8%) |
| Empa/1000 mg Glumetza ® (Fed) | — | 0/24 (0%) | 4/24 (16.7%) |
| Empa/ 1000 mg Met FDC (Fed) | — | 0/24 (0%) | 4/24 (16.7%) |
| Empa/ 1500 mg Glumetza® (Fasted) | — | 0/24 (0%) | 6/24 (25%) |
| Empa/ 1500 mg Met FDC (Fasted) | — | 0/23 (0%) | 7/23 (30.4%) |
| Event | Empa/1000 mg Glumetza® (Fasted) | Empa/ 1000 mg Met FDC (Fasted) | Empa/1000 mg Glumetza ® (Fed) | Empa/ 1000 mg Met FDC (Fed) | Empa/ 1500 mg Glumetza® (Fasted) | Empa/ 1500 mg Met FDC (Fasted) |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/24 | 2/24 | 0/24 | 2/24 | 0/24 | 4/23 |
| NauseaGastrointestinal disorders | 0/24 | 1/24 | 4/24 | 2/24 | 1/24 | 1/23 |
| Abdominal painGastrointestinal disorders | 0/24 | 1/24 | 0/24 | 1/24 | 3/24 | 2/23 |
| DizzinessNervous system disorders | 1/24 | 2/24 | 0/24 | 0/24 | 2/24 | 2/23 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/23 |
Treated set which included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.
| Age, Continuous(years) | 1000mg, Fasted | 1000mg, Fed | 1500mg, Fasted | Total |
|---|---|---|---|---|
| Mean | 28.5 ± 8.7 | 32.4 ± 9.1 | 31.3 ± 8.7 | 30.7 ± 8.9 |
| Sex: Female, Male(Participants) | 1000mg, Fasted | 1000mg, Fed | 1500mg, Fasted | Total |
|---|---|---|---|---|
| Female | 16 | 16 | 16 | 48 |
| Male | 8 | 8 | 8 | 24 |
The record gives a start of Apr 2014, a primary completion of Jun 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Metformin